These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

456 related items for PubMed ID: 9753311

  • 21. The increased risk of venous thromboembolism and the use of third generation progestagens: role of bias in observational research. The Transnational Research Group on Oral Contraceptives and the Health of Young Women.
    Lewis MA, Heinemann LA, MacRae KD, Bruppacher R, Spitzer WO.
    Contraception; 1996 Jul; 54(1):5-13. PubMed ID: 8804801
    [Abstract] [Full Text] [Related]

  • 22. The new era in oral contraception: pills containing gestodene, norgestimate, and desogestrel.
    London RS.
    Obstet Gynecol Surv; 1992 Nov; 47(11):777-82. PubMed ID: 1436906
    [Abstract] [Full Text] [Related]

  • 23. Desogestrel, norgestimate, and gestodene: the newer progestins.
    Kaplan B.
    Ann Pharmacother; 1995 Nov; 29(7-8):736-42. PubMed ID: 8520092
    [Abstract] [Full Text] [Related]

  • 24. A comparative study of the effects of the hemostatic system of two monophasic gestodene oral contraceptives containing 20 micrograms and 30 micrograms ethinylestradiol.
    Winkler UH, Schindler AE, Endrikat J, Düsterberg B.
    Contraception; 1996 Feb; 53(2):75-84. PubMed ID: 8838483
    [Abstract] [Full Text] [Related]

  • 25. Third-generation oral contraceptives: how risky?
    Weiss N.
    Lancet; 1995 Dec 16; 346(8990):1570. PubMed ID: 7500743
    [Abstract] [Full Text] [Related]

  • 26. The role of triphasic levonorgestrel in oral contraception: a review of metabolic and hemostatic effects.
    Lachnit-Fixson U.
    Gynecol Endocrinol; 1996 Jun 16; 10(3):207-18. PubMed ID: 8862497
    [Abstract] [Full Text] [Related]

  • 27. The differential risk of oral contraceptives: the impact of full exposure history.
    Lewis MA, MacRae KD, Kühl-Habichl D, Bruppacher R, Heinemann LA, Spitzer WO.
    Hum Reprod; 1999 Jun 16; 14(6):1493-9. PubMed ID: 10359554
    [Abstract] [Full Text] [Related]

  • 28. Use of oral contraceptives containing gestodene and risk of venous thromboembolism: outlook 10 years after the third-generation "pill scare".
    Heinemann LA, Dinger JC, Assmann A, Minh TD.
    Contraception; 2010 May 16; 81(5):401-7. PubMed ID: 20399946
    [Abstract] [Full Text] [Related]

  • 29. First-time use of newer oral contraceptives and the risk of venous thromboembolism.
    Suissa S, Blais L, Spitzer WO, Cusson J, Lewis M, Heinemann L.
    Contraception; 1997 Sep 16; 56(3):141-6. PubMed ID: 9347203
    [Abstract] [Full Text] [Related]

  • 30. The risks of venous thromboembolic disease among German women using oral contraceptives: a database study.
    Farmer RD, Todd JC, Lewis MA, MacRae KD, Williams TJ.
    Contraception; 1998 Feb 16; 57(2):67-70. PubMed ID: 9589831
    [Abstract] [Full Text] [Related]

  • 31. Changes in the plasma levels of proteins C and S in young women on low-dose oestrogen oral contraceptives.
    Granata A, Sobbrio GA, D'Arrigo F, Barillari M, De Luca P, Egitto M, Granese D, Pullè C, Trimarchi F.
    Clin Exp Obstet Gynecol; 1991 Feb 16; 18(1):9-12. PubMed ID: 1829030
    [Abstract] [Full Text] [Related]

  • 32. Clinical aspects of the relationship between oral contraceptives and abnormalities of the hemostatic system: relation to the development of cardiovascular disease.
    Kelleher CC.
    Am J Obstet Gynecol; 1990 Jul 16; 163(1 Pt 2):392-5. PubMed ID: 2196811
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Risk of venous thromboembolism with third-generation oral contraceptives: A review.
    Weiss G.
    Am J Obstet Gynecol; 1999 Feb 16; 180(2 Pt 2):295-301. PubMed ID: 9988833
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Myocardial infarction and stroke in young women: what is the impact of oral contraceptives?
    Lewis MA.
    Am J Obstet Gynecol; 1998 Sep 16; 179(3 Pt 2):S68-77. PubMed ID: 9753313
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or desogestrel compared with oral contraceptives containing levonorgestrel.
    Jick SS, Kaye JA, Russmann S, Jick H.
    Contraception; 2006 Jun 16; 73(6):566-70. PubMed ID: 16730485
    [Abstract] [Full Text] [Related]

  • 39. Modeled estimates of myocardial infarction and venous thromboembolic disease in users of second and third generation oral contraceptives.
    Schwingl PJ, Shelton J.
    Contraception; 1997 Mar 16; 55(3):125-9. PubMed ID: 9114999
    [Abstract] [Full Text] [Related]

  • 40. Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study.
    Middeldorp S, Meijers JC, van den Ende AE, van Enk A, Bouma BN, Tans G, Rosing J, Prins MH, Büller HR.
    Thromb Haemost; 2000 Jul 16; 84(1):4-8. PubMed ID: 10928461
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.